Table 3B.

Posttreatment comparison of resveratrol and placebo treated subjects

Clinical Measurement	Placebo (n=14)		Resveratrol (n=14)		p
	Mean±SD	CI 95%	Mean±SD	CI 95%
Clamp M (mg/kg/min)	4.2±1.4	3.4–5.0	4.6±1.8	3.6–5.6	0.525
Insulin (mg/dl)	17±8	13–21	20±16	10–29	0.537
HOMA (%)	4.4±2.2	3.1–5.7	5.0±5.2	2.0–7.0	0.698
120 min data 2 h GTT (mg/dl)	172±39	150–195	139±13	120–158	0 0.023*
AUC (mg/dl)	346±64	309–383	304±42	280–328	0.050*
WBC (k/mcl)	5.9±1.3	5.1–6.7	5.2±1.5	4.3–6.1	0.209
CRP (mg/dl)	0.40±0.20	0 0.28–0.52	0.60±0.41	0.36–0.84	0.111
REE (k/cal/d)	1798±225	1662–1934	1778±228	1640–1976	0.821
BMI (kg/m2)	33.7±3.3	31.8–35.6	34.9±3.0	33.2–36.7	0.331

Comparison of the posttreatment metabolic syndrome characteristics (3A) and laboratory data and BMI (3B) for the total group of resveratrol and placebo treated subjects. *P≤ 0.05. GTT: Oral glucose tolerance test, AUC: Area under the curve, HOMA: Homeostatic model assessment, assesses insulin resistance and beta cell function, WBC: White blood cell count, CRP: C-reactive protein, TG: Serum triglycerides, REE: Resting energy expenditure, BMI:Body mass index, SD: Standard deviation, CI: Confidence interval.